GlassScriptPhysician profile
Jeffrey D Greiff
NPI 1780738054
$1,414.86
in general payments reported to CMS, 2019-2025
22 companies · $98.83 in 2025
The $98.83 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $448 · 2021: $182 · 2022: $107 · 2023: $134 · 2024: $50.57 · 2025: $98.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $283.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $359.69 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $151.59 | 2020-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $115.92 | 2020-2022 | |
| Glaxosmithkline, LLC. | $110.99 | 2019-2020 | |
| Amgen INC. | $90.68 | 2020-2022 | |
| Amarin Pharma, INC. | $84.82 | 2019-2020 | |
| Lilly USA, LLC | $72.66 | 2020-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.47 | 2021-2023 | Jardiance, Trijardy Xr |
| Avanir Pharmaceuticals, INC. | $40.92 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $40.69 | 2023-2025 | Jublia, Cabtreo, Siliq |
| Gilead Sciences, INC. | $37.37 | 2020 | |
| Celgene Corporation | $34.24 | 2019 | |
| Sun Pharmaceutical Industries INC. | $29.48 | 2023 | Ilumya |
| Kowa Pharmaceuticals America, INC. | $27.74 | 2021 | |
| Janssen Biotech, INC. | $24.72 | 2023 | Remicade, Simponi Aria, Simponi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $22.47 | 2021 | |
| Sanofi Pasteur INC. | $20.09 | 2020 | |
| Janssen Pharmaceuticals, INC | $19.59 | 2019 | |
| Abbott Laboratories | $19.03 | 2022 | |
| Astellas Pharma US INC | $17.56 | 2023 | Myrbetriq |
| Tolmar, INC. | $13.49 | 2025 | Jatenzo |
| Alk-Abello, INC | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Greiff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.